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Abstract
Background: Recently, using a mouse model of mucopolysaccharidosis (MPS) IIIB, a lysosomal storage disease with 
severe neurological deterioration, we showed that MPS IIIB neuropathology is accompanied by a robust 
neuroinflammatory response of unknown consequence. This study was to assess whether MPS IIIB lymphocytes are 
pathogenic.
Methods: Lymphocytes from MPS IIIB mice were adoptively transferred to naïve wild-type mice. The recipient animals 
were then evaluated for signs of disease and inflammation in the central nervous system.
Results: Our results show for the first time, that lymphocytes isolated from MPS IIIB mice caused a mild paralytic 
disease when they were injected systemically into naïve wild-type mice. This disease is characterized by mild tail and 
lower trunk weakness with delayed weight gain. The MPS IIIB lymphocytes also trigger neuroinflammation within the 
CNS of recipient mice characterized by an increase in transcripts of IL2, IL4, IL5, IL17, TNFα, IFNα and Ifi30, and 
intraparenchymal lymphocyte infiltration.
Conclusions: Our data suggest that an autoimmune response directed at CNS components contributes to MPS IIIB 
neuropathology independent of lysosomal storage pathology. Adoptive transfer of purified T-cells will be needed in 
future studies to identify specific effector T-cells in MPS IIIB neuroimmune pathogenesis.
Background
Mucopolysaccharidosis IIIB is a lysosomal storage dis-
ease (LSD) with severe neurological manifestations[1].
No treatment for MPS IIIB is currently available. The dis-
ease is caused by autosomal recessive defects in α-N-
acetylglucosaminidase (NaGlu), a lysosomal enzyme
essential in the stepwise degradation of heparan sulfate
(HS), a biologically important glycosaminoglycan
(GAG)[1].
The primary pathology of MPS IIIB is the accumulation
of HS or HS-derived materials in lysosomes in somatic
and central nervous system (CNS)[1,2]. The detailed
mechanisms of MPS IIIB pathology, especially neuropa-
thology, remain unclear although recent studies have
implicated aberrant activation of innate and adaptive
immunity[2-9]. Indeed, immunosupression with predni-
solone was shown to delay the progression of the CNS
disease in MPS IIIB mice[8], supporting the critical con-
tribution of neuroimmunity to the neuropathology of
MPS IIIB.
Although it is unclear how lysosomal HS storage initi-
ates aberrant CNS immune responses, it is perhaps not
surprising considering that abnormal GAG metabolism
has been described in several autoimmune diseases,
including rheumatoid arthritis (RA), scleroderma and
systemic lupus erythematosus (SLE)[10-14]. Heparan sul-
fates are important functional components of numerous
glycoproteins/proteoglycans on cell surfaces and in extra-
cellular matrices where they engage in biologically impor-
tant protein interactions in development and normal
physiology. Numerous glycobiology studies have demon-
strated the active participation of GAGs and their proteo-
glycan backbones in leukocyte functions, including
antigen presentation and leukocyte homing/transmigra-
tion to sites of inflammation[10-12,15-18]. Changes in
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cell surface HS has been shown to modulate the sensitiv-
ity of T-cell responses to diverse activation stimuli[19].
Our recent novel data suggested that enhanced CNS
antigen presentation and lymphocyte activation in the
brains of MPSIIIB mice may be a critical contributor to
the progression of MPS IIIB[8]. Also, the de novo synthe-
sis of CNS-specific antibodies in MPS IIIB mice suggests
that neuroantigens are probable targets of autoimmune
attack during progression of MPS IIIB. A recent study
also showed the potential involvement of cytotoxic T-
c e l l s  i n  n e u r o p a t h o l o g y  o f  M P S  I I I B [ 9 ] .  T o  t e s t  t h i s
hypothesis and thereby confirm lymphocytes as effectors
of pathology in MPS IIIB, we isolated lymphocytes from
MPS IIIB mice and age-matched wild-type (wt) control
mice and then passively immunized naïve wt recipient
mice with these activated cells. Herein we present ana-
tomical, molecular and behavioral evidence that the path-
ological sequelae of MPS IIIB is due in part to the
induction of a CNS autoimmune response.
Methods
Animals
MPS IIIB knock-out mice [2] were maintained on an
inbred background (C57BL/6) by backcrosses of
heterozygotes. This colony has been through 16 back-
crosses, alternated by a cross with wt C57BL/6 to gener-
ate heterozygotes for next backcross. MPS IIIB mice were
housed in the barrier area in the Vivarium at the Research
Institute at Nationwide Children's Hospital (NCH-RI).
Progeny mice were genotyped by PCR. The MPS IIIB
mice and their age-matched wt littermates were used in
the experiments. All procedures using MPS IIIB mice in
this study have been approved by the Institutional Animal
Care and Use Committee at NCH-RI. All care and proce-
dures were in accordance with the Guide for the Care and
Use of Laboratory Animals [DHHS Publication No. (NIH)
85-23]. MPS IIIB mice and control wt littermate were
used in all experiments in this study.
Lymphocyte preparation
Mice were anesthetized with an intraperitoneal injection
of Avertin (0.3 - 0.4 μg/g) and spleens were dissected for
lymphocyte preparation, following established proce-
dures. 1) Under sterile conditions, cell suspensions in
RPMI media containing 2% FBS were filtered through a
70 μm nylon cell strainer. 2) The cells were washed and
resuspended in Fac's buffer (PBS, 2% fetal calf serum), 3)
then incubated with RBC lysis buffer (eBioscience) to
remove red blood cells, and 4) washed and resuspended
in Fac's buffer or RPMI media for further analysis. The
number of splenocytes was determined using Sysmex
KX-2IN Automated Hematology Analyzer after step 1)
and again at the end of the process.
Adoptive transfer
Splenocytes from 2-3-month-old MPS IIIB mice were
isolated as described above. Single cell suspension of
splenocytes isolated from multiple mice were pooled and
stimulated in vitro for 48 hours with Concanavalin A
(ConA, 1 μg/ml) in RPMI 1640 growth media (10% FBS, 2
mM L-glutamine, 100 U/ml penicillin 100 μg/ml strepto-
mycin and 50 μM 2-ME). The non-adherent cells were
collected and washed with PBS for adoptive transfer. The
isolated lymphocytes (2 × 107/mouse) were injected
intravenously (IV) into 10-12-week-old wt male litter-
mates through tail vein. The mice were then observed
daily for their wellbeing and clinical disease signs over 2-6
weeks. Lymphocytes isolated from age-matched wt litter-
mates were IV injected into age-matched wt littermates
as controls.
Clinical evaluation
Mice were examined daily to identify any abnormalities.
After observing a mild ascending paralytic clinical dis-
ease in animals receiving MPS IIIB lymphocytes, we
adopted a scoring system used in evaluation of experi-
mental autoimmune encephalomyelitis (EAE)[20] to
assess mice in this study. The scoring system was on a
scale of 0-5: 0 = no clinical disease; 1 = tail weakness; 1.5
= tail paralysis; 2 = hind limb weakness; 3 = hind limb
paralysis; 3.5 forelimb weakness; 4 = forelimb paralysis; 5
= moribund or death.
Grip tests
Grip tests were performed at 14 days after the adoptive
transfer to evaluate the strength of limbs, using a digital
grip strength meter (Columbus instruments). The grip
strength was presented as peak tension (g).
Activity measures
Exploratory activity in a novel environment was assessed
in a one-hour trial in a photobeam open field chamber
[21](San Diego instruments). Counts were taken of the
number of photobeams broken during the trial, with sep-
arate measures for locomotor, vertical, and rearing activ-
ity.
Rotarod
Subjects were tested on an accelerating rotarod (Med
Associates Inc.) to assess motor coordination [21]. For
the first test session, animals were given three trials, with
45 seconds between each trial. Two additional trials were
given 48 hours later. Revolutions per minute (rpm) was
set at an initial value of 3, increasing to a maximum of 30
rpm across five minutes (the trial length). Measures were
taken for latency to fall from the rotating barrel (sec).Killedar et al. Journal of Neuroinflammation 2010, 7:39
http://www.jneuroinflammation.com/content/7/1/39
Page 3 of 8
Tissue sample collection
Tissue samples were collected at 14 days, and 5 weeks
after adoptive transfer. The animals were anesthetized
with an intrperitoneal injection of 2.5% Avertin, blood
samples were collected. The mice were then perfused
transcardially with 20 ml of cold PBS (0.1 M, pH7.4), and,
for histological examinations, followed by 4% para-
formalde, prior to tissue collection. Brain, spinal cord and
spleen samples were collected. The half brain samples
and spinal cords were stored at -80°C before being pro-
cessed for total RNA extraction. Tissue samples from
paraformaldehyde-perfused animals were further fixed in
4% paraformaldehyde overnight, then infiltrated in 3%
sucrose, and then embedded in OCT for cryosectioning,
and histology and immunohistochemistry staining. Each
assay was performed using samples from at least 4 mice
(n ≥ 4/group).
Flow cytometry (FC)
Flow cytometry was performed on donor splenocytes (4
× 106 lymphocytes per sample), expanded with ConA,
using antibodies against mouse CD3e, CD4, CD8, CD25,
CD45R/B220, and F4/80 (BD Biosciences). The labeled
cells were sorted using a BD-LSRII flow cytometer (BD
Biosciences) and data were analyzed using BD FACSDiva
software.
T-cell proliferation assay
Freshly isolated splenocytes were assayed for T-cell pro-
liferation following published procedures [22,23] using
freshly isolated cells with anti-mouse-CD3e antibody
(eBioscience) as stimulator, and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) as cell pro-
liferation marker. Cells in RPMI growth media (2 × 105 in
200 μl/well, in triplicates or more) were plated onto 96-
well tissue culture plates pre-coated with anti-CD3e anti-
body (50 μl, 10 μg/ml in PBS) or PBS, and incubated at
37°C for 72 hr. The cell clusters formed in each well were
then counted under a microscope, before the addition of
20 μl MTT buffer (5 mg/ml in PBS), followed by 4-hour
incubation. The MTT lysis buffer (20% SDS in 50% DMF)
was then added to each well and incubated at 37°C over-
night. T-cell proliferation was expressed as: Stimulation
index = A570 with anti-CD3/A570 with PBS.
Bio-plex cytokine assay
Splenocytes (106 cells/ml) were incubated in RPMI 1640
growth media, as described above, in the presence or
absence of ConA. Media were collected after 42 hour
incubation, and assayed for cytokine production by Bio-
plex cytokine assay (BioRad), following the procedures
provided by the manufacturer. The Bio-plex panel used
targets IL2, IL4, IL5, IL10, IL17, IFNγ and TNFα.
RNA and qRT-PCR
Total RNA was isolated from half brain of each individual
mouse (n = 4/group), using SV Total RNA Isolation Sys-
tem (Promega), following the manufacturer's protocols.
The isolated total RNA samples were then further puri-
fied through an RNeasy spin column (Qiagen). The
mouse brain total RNA was assayed for the expression of
immune-associated genes, using sequence specific prim-
ers. A pair of primers for murine GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) gene was used as
internal control. Superscript™ First-strand Synthesis Sys-
tem for RT-PCR (Invitrogen) was used for cDNA synthe-
sis. The qRT-PCR was performed using SYBR® Green
PCR Master Mix (Applied Biosystems). Comparative
threshold (CT) method was used for data analysis. Data
were expressed as relative quantitation of gene expression
(2^-ΔΔCt)[24], in the brain of mice given an adoptive trans-
fer of lymphocytes from MPS IIIB mice vs. lymphocytes
from wt mice.
Immunohistochemistry (IHC)
Mouse brain tissues were processed for serial transverse
cryostat sections (10-15 μm). IHC staining was per-
formed following the procedures provided by manufac-
turers, using primary antibodies against mouse CD3
(AbD Serotec) and CD8 (Biolegend), and secondary anti-
bodies conjugated with horse radish peroxidase or Alexa
Fluo 568.
Statistical analysis
Data are reported as means ± SD. P-values between data-
sets were determined by two-tailed Student's t-test. Sig-
nificance was defined as P < 0.05.
Results
MPS IIIB causes spontaneous activation of the adaptive 
immune system
To test our hypothesis that MPS IIIB primes an autoim-
mune response which subsequently provokes the onset or
exacerbates MPS IIIB neuropathology, we analyzed the
phenotype and functional potential of MPS IIIB mouse
lymphocytes. T-cell proliferation assay showed a signifi-
cant increase in stimulation index of splenic lymphocytes
from MPS IIIB mice, compared to wt cells, when stimu-
lated with anti-CD3e ex vivo (data not shown), suggesting
T - c e l l  a c t i va t i o n  i n  M P S  I I I B  m i c e .  T o  be  u s e d  i n  t h e
adoptive transfer experiments below, splenic lympho-
cytes isolated from wt (10-12 weeks old) or MPS IIIB
mice (n = 8/group) were pooled within a group. Leuko-
cyt e s  f r o m  wt  o r  M PS  II IB  m i c e  w e r e  c o m p ri sed  o f  a
mixed population of T cells, B cells and macrophages
(Table 1). Interestingly, the splenic T:B cell ratio was
reduced 26% in MPS IIIB mice and was accompanied by
an increase in F4/80+ macrophages, suggesting the acti-Killedar et al. Journal of Neuroinflammation 2010, 7:39
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vation of B-cells and macrophages. T cells from MPS IIIB
mice spontaneously (i.e., without ex vivo stimulation)
secreted more cytokine at higher concentrations than T
cells from wt mice. Specifically, we found IL2, IL4, IL5,
IL10, IL17 and IFNγ to be present in supernatants of T
cells from MPS IIIB mice but not wt mice (data not
shown). After stimulation with concanavilin A (ConA),
MPS IIIB lymphocytes secreted greater amounts of IL2,
IL5, IL10, IFNγ and TNFα as compared to ConA-acti-
vated wt lymphocytes (Fig. 1). These data suggest that T
cells are activated in vivo during the progression of MPS
IIIB and develop a predominantly Th1 cytokine profile
(i.e., high levels of IL-2 and IFNγ).
MPS IIIB lymphocytes cause neurological impairment
Adoptive transfer of isolated lymphocytes was performed
to assess the pathogenic potential of MPS IIIB lympho-
cytes. Because our previous studies showed that the CNS
imm une activation in MPS IIIB mice involves virtually
every aspect of the immune system, total mouse splenic
lymphocytes were used for adoptive transfer in this study.
Lymphocytes that were pooled from the spleen of age-
matched donor MPS IIIB or wt mice were activated with
ConA ex vivo for 48 hours then were injected intrave-
nously into naïve wt recipient mice (n = 26-38 recipient
mice/group, 8-10 weeks old). All recipient mice were
monitored daily for signs of neurological impairment
using a 0-5 "clinical scale" that is widely used to quantify
the magnitude of ascending paralysis in experimental
autoimmune encephalomyelitis (EAE)[20]. None of the
mice treated with wt lymphocytes developed disease. In
contrast, all mice receiving lymphocytes from MPS IIIB
donor mice developed mild ascending paralysis charac-
terized by weak tail and lower trunk (score of ~1) (Table
2, Fig. 2a, Additional files 1, 2, 3, 4). Tail weakness
emerged 6-9 days after adoptive transfer and persisted for
up to 15 days reaching peak disease at ~2 weeks post
transfer (Table 2; Fig. 2a).
Given the subjective nature of the clinical scale, addi-
tional behavioral assays were completed to confirm and
quantify the magnitude of neurological impairment. Spe-
cifically, we quantified grip strength, volitional open field
activity and latency on rotarod at 2 weeks post transfer,
i.e., the time of peak clinical disease. As shown in Fig. 2b,
hind limb grip strength was significantly impaired in
mice injected with MPS IIIB lymphocytes (P < 0.05 vs.
mice injected with wild-type lymphocytes). Fore limb
grip strength was unaffected (not shown). Hind limb def-
icits were confirmed in the open field and on the rotorod,
where a significant decrease in rearing activity (P < 0.05)
and shorter latencies to fall were noted in mice treated
with MPS IIIB lymphocytes (Fig. 2c&2d).
To further assess the pathological impact of adoptively-
transferred MPS IIIB lymphocytes, we monitored the
body weight of mice born on the same day that received
either wt or MPS IIIB lymphocytes (n = 6-8 recipient
mice/group). All mice had equal access to food and water
each day during the analysis period. Mice treated with
wild-type lymphocytes increased their body weight ~16%
over baseline in 20 days (Fig. 2e). In contrast, mice that
received MPS IIIB lymphocytes increased their body
weight 5% by the end of the observation period (i.e., 40
days post-transfer). This significant delay in weight gain
paralleled the onset and progression of neurological
impairment. Collectively, these data suggest that MPS
IIIB lymphocytes cause neurological impairment and a
sustained sickness response.
Adoptively transferred MPS IIIB lymphocytes alter CNS 
gene expression and promote intraparenchymal 
inflammation and glial activation
To evaluate the impact of adoptively transferred MPS IIIB
lymphocytes on the nervous system of recipient mice, we
used qRT-PCR to compare mRNA profiles of brains pre-
pared from mice receiving wild-type or MPS IIIB lym-
phocytes at the peak of clinical disease (2 weeks post-
transfer). We observed a significant up-regulation of
Figure 1 Enhanced cytokine production by MPS IIIB lymphocytes. 
Donor splenocytes isolated from 2-3-month-old MPS IIIB (n = 8) or wt 
mice (n = 8) were pooled and incubated for 48 hrs in RPMI 1640 
growth media in the presence of ConA (1 μg/ml). The media were then 
assayed for cytokines by Bio-plex assay. The data here were means 
from two sets of independent experiments (n = 8/group/experiment). 
Each sample was analyzed in duplicates. +/+: wt; -/-: MPS IIIB. *: P < 
0.01; #: P < 0.05.
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Table 1: Donor splenic lymphocyte population *Splenocyte 
population (%)
Donor B220+ CD3+ F4/80+
mice CD4+ CD8+
wt 47.7 22.2 15.2 8.25
MPS IIIB 55.5 14.6 14.5 14.1
*Splenic lymphocytes isolated from age-matched (10-12-week-
old) male MPS IIIB or wt mice were pooled and stimulated with 
ConA (1 μg/ml in RPMI growth media) for 48 hrs. Data represent 
the average of two independent experiments (n = 8 donors/
group/experiment).Killedar et al. Journal of Neuroinflammation 2010, 7:39
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markers of innate immunity and glial activation (i.e.,
CD45, CD68, GFAP) along with a significant increase in
expression of multiple cytokines, including IFNγ, IL2,
IL4, IL5, IL17, TNFα, IFNα and Ifi30 (Table 3). Western
blotting for GFAP confirmed the astrocyte activation
(data not shown). We also noted a modest increase in
CD3e, CD4 and CD8a mRNA suggesting the presence of
T-cell infiltrates in the CNS of mice receiving MPS IIIB
lymphocytes (Table 3). Immunofluorescence staining of
brain cryosections from recipient mice confirmed this
hypothesis showing the presence of CD8+ T-cells in the
brain and spinal cord of mice receiving MPS IIIB lympho-
cytes at 2 weeks (Fig. 3) but not at 4 weeks post transfer.
The distribution of these T-cells was sporadic without
evidence of profound clustering (as in EAE). Immuno-
flurescence for CD3 and CD4 was not successful due to
Table 2: Clinical disease induced in naïve wild-type recipient mice by adoptive transfer of lymphocytes from MPS IIIB mice
*Lymphocyte Donor Disease Incidence at peak (14d pi) Day of onset **Mean peak clinical score
+/+ 0/20 (0%) n/a 0
-/- 30/30 (100%) 7.4 ± 1.1 0.9 ± 0.2
In total, 26 and 38 mice received adoptive transfer of wt and MPS IIIB lymphocytes, respectively. Data here include only mice that went 
through complete disease observation. The rest of mice were terminated for tissue analysis at 1 week post transfer and were not included in 
this table.
* +/+: wt mice; -/-: MPS IIIB mice. ** Peak: 2 weeks post transfer.
Figure 2 Pathogenic effects of the adoptive transfer of MPS IIIB lymphocytes. Splenocytes isolated from multiple 2-3-month-old MPS IIIB mice 
were pooled and stimulated in vitro with 1 μg/ml Con A for 48 hours. The activated non-adhesive cells were then isolated and injected IV into 8-10-
week-old wt mice (n = 20). The controls were the wt mice treated with an IV injection of wt lymphocytes (n = 20). The mice receiving MPS IIIB lym-
phocytes developed mild EAE-like clinical disease (a), with decreased hindlimb grip strength (b), impaired rearing activity (c), reduced latency on ro-
tarod (d), and delayed growth (e). +/+: adoptive transfer of wt lymphocytes; -/-: adoptive transfer of MPS IIIB lymphocytes. *: P < 0.01 wt cell-treated 
vs. MPS IIIB cell-treated mice;: P < 0.05 vs. day 8; #: P < 0.01 vs. day 8. The bw differences of MPS IIIB cell recipients vs. wt cell recipients from day 8-40 
were significant (P < 0.05).
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the quality of the antibodies that did not even stain cells
in spleen. We did not find T cells in the brain or spinal
cord of mice receiving injections of wild-type lympho-
cytes.
Discussion
Our recent studies have shown that lymphocytosis is a
natural consequence of MPS IIIB[8]. In this study, we
show that T-cells in MPS IIIB mice become activated
spontaneously in vivo. Although we have not yet defined
the mechanisms responsible for T cell activation in this
model, we show for the first time that these cells have the
ability to cause neurological impairment when they are
adoptively transferred into naïve wt recipient mice. These
data suggest that MPS IIIB primes an autoimmune
response, which subsequently provokes the onset or
exacerbates MPS IIIB neuropathology. Given the impor-
tant role of HS in modulating the sensitivity of T cells and
antigen presenting cells to activation[10-12,19,25-27] and
the involvement of abnormal GAG metabolism in auto-
immune diseases[10-14], it is likely that lysosomal HS
storage initiates aberrant immune responses culminating
in the onset of an autoimmune reaction.
Based on our past and present data, we predict that a
subset of the activated MPS IIIB lymphocytes are CNS-
reactive and that these cells can impair neurological func-
tion independent of any neuropathology caused by aber-
rant lysosomal HS storage. The temporary and mild
neurological impairment that we observed in naive wt
recipient mice is similar to the course of disease that is
induced after transfer of autoimmune lymphocytes from
rats with traumatic spinal cord injury[28]. Accordingly,
like in that study, it is doubtful that transferred lympho-
cytes cause demyelination or neuronal injury. Instead
MPS IIIB lymphocytes alter brain homeostasis with evi-
dence of glial activation and significantly increased
expression of cytokines (IL2, IL4, IL5, IL17, IFNγ) that
are known cause pathological changes in experimental
models of Th1-mediated CNS autoimmunity[29,30].
Importantly, pro-inflammatory Th1 cytokines can block
neuronal function without triggering cell death or overt
neuropathology[31]. It is likely that Th17 may also be
involved in the adoptive-transfer-mediated change in the
CNS, given that IL17-producing CD4+ T-cells have been
shown to play a fundamental role in different models of
autoimmune diseases[32].
It is worth noting that even though adoptive transfer of
MPS IIIB lymphocytes causes global changes in CNS
cytokine expression with neurological impairement,
these changes are mild compared to those elicited by pas-
sive immunization with myelin-reactive T cells and the
onset of EAE. Without adjuvant priming - a necessary
Table 3: Effect of adoptive transfer of MPS IIIB lymphocytes on the expression of immune-associated genes in the brain of 
recipient mice
Gene symbol Gene name GenBank access # #2-ΔΔCt (fold of increase)
IFN-γ Interferon gamma NM_008337 17.8*
CD68 CD68 antigen NM_009853 5.2*
GFAP Glial fibrillary acidic protein NM_010277 4.1*
IL4 Interleukin 4 NM_021283 2.8*
IL5 Interleukin 5 NM_010558 1.7*
IL6 Interleukin 6 NM_031168 1.3
IL17 Interleukin 17 NM_010552 2.1*
IL2 Interleukin 2 NM_008366 1.9*
TNF-α Tumor necrosis factor alpha NM_013693 1.9*
CD45 Protein tyrosine phosphatase receptor type C NM_011210 1.7*
Ifi30 Interferon gamma inducible protein 30 NM_023065 1.8*
IFN-α Interferon alpha NM_008334 1.6*
CD3e CD3 antigen, epsilon polypeptide NM_007648 1.3*
CD4 CD4 antigen NM_013488 1.4*
CD8a CD8 antigen, alpha chain NM_001081110 1.2
IL10 Interleukin 10 NM_010548 1.0
#Real-time qRT-PCR data were analyzed by means of the comparative threshold (CT) method using mouse GAPDH as internal control and 
expressed as 2-ΔΔCt. These changes reflect relative increases in gene expression in the brain of mice receiving MPS IIIB lymphocytes (n = 4) as 
compared to wild-type lymphocytes-treated mice (n = 4). *P < 0.05 (ΔΔCt of MPS IIIB lymphocytes-treated mouse brains vs. wild-type 
lymphocytes-treated mouse brains).Killedar et al. Journal of Neuroinflammation 2010, 7:39
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feature of EAE induction[33-35], the threshold and fre-
quency of CNS-reactive T cells is expected to be lower in
MPS IIIB mice. Also, even though it is clear that the
i n d u c t i o n  o f  a n  a u t o i m m u n e  r e s p o n s e  d i r e c t e d  a t  t h e
CNS is associated with aberrant lysosomal HS storage[8],
the identities of the autoantigens that trigger this
response are currently unknown. For this reason, we were
unable to activate MPS IIIB splenocytes ex vivo using
antigen-specific stimulation. Instead, ConA was used as a
polyclonal stimulant. Thus, only a fraction of transferred
lymphocytes would be expected to be pathogenic or spe-
cific for CNS proteins, the remaining cells may have regu-
latory or anti-inflammatory functions as described in
other models of nerve injury and autoimmune dis-
eases[36-38].
Conclusion
We have demonstrated for the first time the pathogenic
property of MPS IIIB lymphocytes, a subset of which can
traffic to the CNS where they promote neuroinflamma-
tion with neurological impairment. The neuropathogene-
sis of lymphocytes is likely a critical contributor to the
neuropathology of MPS IIIB, which is independent of the
lysosomal storage pathology. Since the onset of this path-
ological neuro-immune reaction arises predictably in
MPS IIIB mice without concomitant infection or injury,
this model may be useful for studying novel signaling
pathways and activation mechanisms that are responsible
for controlling pathological CNS-immune interactions.
Given the central role of T-cells in autoimmune
responses, further studies using purified T-cells will be
critical for investigating the neuropathogenic role of spe-
cific autoimmune effector T-cells in MPS IIIB.
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